Abstract

The primary objective of this SBIR phase I contract is to prepare a new clinical batch of the 30-day naltrexone microcapsule formulation under cGMP. This batch of microcapsules will be packaged in glass vials, sterilized, and fully characterized in accordance with BIOTEK standard operating procedures. Stability studies of the formulation will be initiated.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Small Business Innovation Research – Phase I (N43)
Project #
N43AA082007-000
Application #
2835275
Study Section
Project Start
1998-07-06
Project End
Budget Start
1998-07-06
Budget End
1999-01-05
Support Year
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
Biotek, Inc.
Department
Type
DUNS #
City
Woburn
State
MA
Country
United States
Zip Code
01801